PCV13 in the USA: Early successes and potential challenges

The Lancet Infectious Diseases

Volumn 15, Issue 3, 2015, Pages 254-256

  Stockmann, Chris ^a,b   Byington, Carrie L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

HUMAN; LICENSING; NONHUMAN; NOTE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SEROTYPE; UNITED STATES; VACCINATION; BACTEREMIA; FEMALE; IMMUNOLOGY; MALE; MENINGITIS, BACTERIAL; PNEUMOCOCCAL INFECTIONS;

BACTEREMIA; FEMALE; HUMANS; MALE; MENINGITIS, BACTERIAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84923284734     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70018-6     Document Type: Note

References (14)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011, 331:430-434.
3. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention (CDC).
4. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295:1668-1674.
5. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013, 10:e1001517.
6. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, published online Feb 3. http://dx.doi.org/10.1016/S1473-3099(14)71081-3.
7. Guevara M, Ezpeleta C, Gil-Setas A, et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine 2014, 32:2553-2562.
8. Iroh Tam PY, Madoff LC, Coombes B, Pelton SI Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics 2014, 134:210-217.
9. Spijkerman J, Prevaes SM, van Gils EJ, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PloS One 2012, 7:e39730.
10. Review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV-7) use and implications for the PCV10/PCV13 era 2012, WHO, World Health Organization, Geneva.
11. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
12. Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013, 31:6232-6238.
13. Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015, 33:359-366.
14. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643.